RichardJCoteMDFRCPath, FCAP
Pathology • Saint Louis, MOGenitourinary Pathology, Anatomic Pathology, Clinical Pathology, Surgical Pathology
Professor and Chair, Department of Pathology and Immunology at Washington Univeristy School of Medicine in St. Louis
Dr. Cote is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Barnes Jewish Hospital Plz
# Div
Saint Louis, MO 63110Phone+1 314-362-5641Fax+1 314-362-0369
Summary
- Dr. Richard Cote is the Chair of the Department of Pathology and Immunology at Washington University School of Medicine in St. Louis and is the Chief of the Pathology Service at Barnes-Jewish Hospital. Previously he was Chair of Pathology at University of Miami, and prior to that was a member of the faculty at the University of Southern California Keck School of medicine. He received his medical degree from University of Chicago Division of the Biological Sciences The Pritzker School of Medicine and has been in practice 37 years. He specializes in genitourinary pathology, anatomic pathology, clinical pathology, and surgical pathology and is experienced in breast cancer, genitourinary cancer, prostatectomy, biopsies, and adenocarcinoma.
Education & Training
New York University School of MedicinePost-Doctoral Fellowship, 1989 - 1990
Chief Fellow - Memorial Sloan-Kettering Cancer CenterPathology, 1988 - 1990
Memorial Sloan Kettering Cancer CenterFellowship, Surgical Pathology, 1987 - 1988
New York Presbyterian Hospital (Cornell Campus)Residency, Pathology-Anatomic and Clinical, 1985 - 1987- Memorial Sloan Kettering Cancer CenterPost-Doctoral Fellowship, 1981 - 1983
University of Michigan Health SystemInternship, Surgical Internship, 1980 - 1981
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1980
Certifications & Licensure
IL State Medical License 2020 - 2026
MO State Medical License 2019 - 2026
FL State Medical License 2008 - 2025
CA State Medical License 1990 - 2022- American Board of Pathology Anatomic Pathology
Awards, Honors, & Recognition
- Saint Louis Magazine Top Doctor Saint Louis Magazine, 2020-2022
- America's Top Doctors for Cancer Castle Connolly, 2005-2022
- America's Top Doctors Castle Connolly, 2002-2022
- Join now to see all
Clinical Trials
- 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer Start of enrollment: 1997 Aug 01
- Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management Start of enrollment: 2012 Aug 01
- MRI Based Active Selection for Treatment Trial Start of enrollment: 2014 Nov 12
Publications & Presentations
PubMed
- Length-scale study in deep learning prediction for non-small cell lung cancer brain metastasis.Haowen Zhou, Siyu Lin, Mark Watson, Cory T Bernadt, Oumeng Zhang
Scientific Reports. 2024-09-27 - Impact of Stain Variation and Color Normalization for Prognostic Predictions in Pathology.Siyu Steven Lin, Haowen Zhou, Richard J Cote, Mark Watson, Ramaswamy Govindan
Arxiv. 2024-09-12 - 4 citationsAI-guided histopathology predicts brain metastasis in lung cancer patients.Haowen Zhou, Mark Watson, Cory T Bernadt, Steven Siyu Lin, Chieh-Yu Lin
The Journal of Pathology. 2024-05-01
Other
- Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladderCote RJ, Mitra AP, Penson DF, Birkhahn M
http://www.uptodate.com/contents/urine-biomarkers-for-the-detection-of-urothelial-transitional-cell-
UpToDate, Wolters Kluwer Health - 2012-08-02
Press Mentions
Huang Named Head of Pathology & ImmunologySeptember 12th, 2024- Medicare Approves Genetic Test for Solid TumorsFebruary 22nd, 2024
- Obituary: Emil Raphael Unanue, Renowned Immunologist, 88December 24th, 2022
- Join now to see all
Grant Support
- A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancerNIH/National Cancer Institute2018–2023
- Miami Clinical and Translational Science InstituteNIH2012–2017
- Culturing Viably Captured Circulating Tumor Cells Using Conditional ReprogrammingNIH/National Cancer Institute2013–2015
- Development of Laser Mediated Nanodroplet Real-Time PCR on Circulating Tumor Cells (CTC) Captured by Microfilter PlatformDOD2012–2014
- Integrated Biomarker Profiling for Individualized Prostate Cancer TherapyBankhead-Coley Cancer Research Program2010–2013
- Integrated Device for Circulating Tumor Cell Capture, Characterization and Lens- Free MicroscopyDepartment of Defense/Breast Cancer Research Program Synergistic Idea Award2009–2012
- Molecular Analysis of Neoadjuvant Platinum in Triple Negative Breast CancerNIH/National Cancer Institute2009–2012
- Integrated Microdevice To Capture And Detect Circulating Tumor CellsNational Cancer Institute2010–2011
- Validation of MAP2K6 as a Therapeutic Target for Metastatic Bladder CancerNIH/National Cancer Institute2009–2010
- Molecular Analysis Of Neoadjuvant Platinum In Triple Negative Breast CancerNational Cancer Institute2009–2010
- Circulating Tumor Cell Capture &Analysis In A Multi-Center Prostate Cancer TrialNational Cancer Institute2009–2010
- Multiplexed Nanosensing For DNA And ProteinsNational Institute Of Biomedical Imaging And Bioengineering2008–2009
- Multiplexed Nanosensing For DNA And ProteinsNational Institute Of Biomedical Imaging And Bioengineering2007–2008
- Integrated Microdevice To Capture And Detect Circulating Tumor CellsNational Cancer Institute2006–2007
- Mcav In Organ-Confined Bladder CA Based On P53 StatusNational Cancer Institute2003–2006
- Bone Marrow &Sentinel Node Micrometastases In Breast CANational Cancer Institute2000–2004
- Detection Of Occult Metastases In Lung Cancer PatientsNational Cancer Institute2000–2003
- Molecular /Cellular Pathways Of Bladder Cancer ProgressionNational Cancer Institute2002
- Core--PathologyNational Cancer Institute2002
- Pilot--Genitourinary CancerNational Cancer Institute2001–2002
- MVAC In Organ-Confined Bladder Cancer Based P53 StatusNational Cancer Institute2001–2002
- MVAC In Bladder Cancer Based On P53 StatusNational Cancer Institute1999
- Molecular/Cellular Pathways Of Bladder Ca++ ProgressionNational Cancer Institute1996–1999
- MVAC In Organ-Confined Bladder Cancer Based On P53 StatuNational Cancer Institute1998
- Generation And Analysis Of Human Monoclonal AntibodiesNational Cancer Institute1985
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
